Singapore’s National Platform for Diagnostics Development

DxD Hub is a one-of-a-kind organisation dedicated to leading MedTech innovation through partnerships and an undiminished passion for creating positive health outcomes. As well-recognised productisation experts, we partner with some of the most exciting companies to successfully bring their products to market.

Our Capabilities

We are the leading end-to-end productisation partner in Southeast Asia with an unparalleled track record. Our co-development approach and proven methodology expedite diagnostics product development and de-risk the commercialisation process for our partners.

Find out more about our capabilities

Our Culture

Being a “Hubber” is a matter of immense pride for our team members. We are humbled by the responsibility we have for healthcare, and we are equally grateful for this opportunity to be able to contribute. The ongoing support, appreciation and encouragement inspire us to push our boundaries, take risks, and lead with energy, passion, and urgency. The culture of inclusion and the awareness of our work’s impact empower us to explore new possibilities and enter new paradigms.

Find out how you can join the team

Our Culture

The Journey So Far

Founded in 2014, DxD Hub has been growing in both size and scale. With our deep understanding of the market, our unique set of capabilities, and our unparalleled track record, we have developed very effective and rewarding partnerships with both public and private sector organisations.

Nov 2014

DxD Hub was launched by then Second Minister for Trade and Industry, Mr S Iswaran.

Jan 2015

Illustration of an award ribbon

DxD Hub attained ISO 13485 IVD design
and development certification.

May 2017

Illustration of a computer

Laennec® (co-developed with HistoIndex and SGH) is the world’s first stain-free digital pathology imaging system approved for clinical diagnosis of liver diseases.

May 2019

Illustration of drops of liquid

GASTROClear (co-developed with MiRXES, SGCC, NUH, and TTSH), approved as a Class 3 IVD, is the world’s first miRNA blood test for early detection of gastric cancer.

Jul 2019

ParkwayHealth Laboratory logo

Tissue PD-L1 Triplex™ (co-developed with Lucence, IMCB and SGH) is the first immunohistochemistry tissue
test for three PD-L1 markers.

Feb 2020

Illustration of testing laboratory equipment

Fortitude 2.0 (co-developed and launched with EDDC, BII, TTSH and licensed to MiRXES) is the first test kit for COVID-19 management in Singapore.

May 2020

May 2020

ASSURE® (co-developed with MP Biomedicals and NUH) is an antibody detection test kit for COVID-19 virus.

May 2020

Illustration of a shield

cPass™ (co-developed with Duke-NUS and GenScript) is a novel surrogate test for COVID-19 viral neutralisation antibodies.

May 2020

Illustration of a rectangular watch with a heart in the middle

Respiree Monitor (co-developed with Respiree and SBIC) is a wearable device that can predict worsening conditions in COVID-19 patients.

Jun 2020

Jun 2020

RESOLUTE 2.0 (co-developed with DSO) is a one-step RT-PCR test for COVID-19 eliminating the need for an additional RNA extraction kit.

Jun 2020

Illustration of a claw machine

RAVE (co-developed with AMT, ARTC, and SIMTech) was developed as an automated lab system that runs RESOLUTE 2.0 in half the time.